港股異動丨石藥集團漲4.44% 旗下三款藥品通過一致性評價
格隆匯11月4日丨石藥集團(1093.HK)漲4.44%,報20.7港元,成交7億港元,總市值1291億港元。石藥集團於上週五午間連發多條公告,公司附屬公司石藥集團歐意藥業有限公司開發的“馬來酸依那普利片(10mg)”已獲中華人民共和國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價;公司附屬公司石藥集團歐意藥業有限公司開發的“鹽酸克林黴素膠囊(0.15g)”已獲中華人民共和國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價;公司附屬公司石藥集團歐意藥業有限公司開發的“頭孢氨苄膠囊(0.125g、0.25g)”已獲中華人民共和國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。瑞信上週發佈研報,重申對石藥“跑贏大市”評級及目標價19.17港元,料公司增長穩固,風險適度平衡,並料公司短期推出新藥品,將可成催化劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.